#ASCO22: Imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival - Endpoints News

Johnson & Johnson and AbbVie popped the cork on some preliminary data showing Imbruvica, the original BTK inhibitor, kept a rare and aggressive form of cancer at bay in combination with two other drugs for more than six years. But will overall survival data c…

The CDC said Friday that one monkeypox patient in the US so far has been treated with SIGA Technologies’ tecovirimat, known commercially as TPOXX, which is an antiviral agent from the strategic natio… [+533 chars]

full article...